Study: Sirtex’s microspheres improve quality of life, but don’t extend survival

Sirtex Medical (ASX:SRX) said today that it’s yttrium-90 resin microspheres did not extend survival significantly compared to Bayer’s sorafenib in a study of patients with hepatocellular carcinoma. Although the 459-patient trial did not meet its primary endpoint, the company reported that patients treated with its microspheres experienced less than half the number of severe, treatment-related adverse effects than those who received the standard, twice-daily systemic treatment with sorafenib.

“Neither sorafenib nor SIR-Spheres Y-90 resin microspheres produced a statistically significant difference in overall survival of the patients we studied,” Dr. Valerie Vilgrain said in prepared remarks. Patients in both arms had a median survival length of 9.9 months following treatment.

Get the full story at our sister site, Drug Delivery Business News.

The post Study: Sirtex’s microspheres improve quality of life, but don’t extend survival appeared first on MassDevice.

from MassDevice http://ift.tt/2pdtuin